Equities analysts expect Syneos Health Inc (NASDAQ:SYNH) to post $0.53 earnings per share for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Syneos Health’s earnings. The highest EPS estimate is $0.59 and the lowest is $0.50. Syneos Health posted earnings per share of $0.60 during the same quarter last year, which indicates a negative year over year growth rate of 11.7%. The firm is expected to announce its next quarterly earnings report on Wednesday, May 9th.
According to Zacks, analysts expect that Syneos Health will report full year earnings of $2.63 per share for the current year, with EPS estimates ranging from $2.52 to $2.81. For the next fiscal year, analysts anticipate that the business will report earnings of $3.13 per share, with EPS estimates ranging from $2.94 to $3.38. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Syneos Health.
A number of equities analysts recently issued reports on SYNH shares. Credit Suisse Group lowered their price target on Syneos Health from $68.00 to $54.00 and set an “outperform” rating on the stock in a report on Tuesday, November 14th. Robert W. Baird set a $46.00 price objective on shares of Syneos Health and gave the company a “buy” rating in a report on Thursday, November 16th. Zacks Investment Research cut shares of Syneos Health from a “hold” rating to a “strong sell” rating in a report on Thursday, November 16th. Mizuho set a $41.00 price objective on shares of Syneos Health and gave the company a “neutral” rating in a report on Friday, December 1st. Finally, SunTrust Banks cut their target price on shares of Syneos Health to $50.00 and set a “buy” rating for the company in a research note on Friday, December 1st. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $49.78.
In other Syneos Health news, CAO Christopher L. Gaenzle sold 1,470 shares of the company’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $41.00, for a total value of $60,270.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.24% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Globeflex Capital L P bought a new position in Syneos Health during the 4th quarter valued at about $210,000. Geode Capital Management LLC bought a new position in Syneos Health during the 4th quarter worth approximately $23,570,000. Finally, Municipal Employees Retirement System of Michigan bought a new position in Syneos Health during the 4th quarter worth approximately $741,000.
Syneos Health (SYNH) traded down $0.15 during midday trading on Friday, hitting $40.50. The company had a trading volume of 874,607 shares, compared to its average volume of 1,102,828. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.23 and a current ratio of 1.23. Syneos Health has a 52-week low of $31.10 and a 52-week high of $61.10. The stock has a market capitalization of $4,230.00, a price-to-earnings ratio of -82.65, a P/E/G ratio of 1.30 and a beta of 0.65.
TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Anticipate Syneos Health Inc (NASDAQ:SYNH) Will Announce Earnings of $0.53 Per Share” was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.thelincolnianonline.com/2018/03/14/zacks-brokerages-anticipate-syneos-health-inc-nasdaqsynh-will-announce-earnings-of-0-53-per-share.html.
Syneos Health Company Profile
Syneos Health, Inc, formerly INC Research Holdings, Inc, is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.